Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Name: Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
License: Public Domain

M.D. Anderson Cancer Center

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

recurrent chronic lymphocytic leukemia, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory small lymphocytic lymphoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 125834
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.